Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 9, 2007

Ipsen Obtains EU Marketing Approval for Short Stature Drug

  • Tercica and Ipsen received European marketing authorization for Increlex® for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency.

    Tercica will receive a milestone payment of EUR 15 million, or approximately $20.55 million, from its EU marketing partner, Ipsen. Since Increlex is under orphan drug designation, the drug will have a 10-year exclusivity period in the EU. It will be sold as a 10-mg/mL solution.

    Tercica has been marketing Increlex in the U.S. since early 2006. The drug’s active ingredient is recombinant human insulin-like growth factor-1 (IGF-1). IGF-1 is the direct mediator of growth hormone’s effect on statural growth and must be present for normal growth of bones and cartilage in children.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »